Short Interest in uniQure N.V. (NASDAQ:QURE) Rises By 33.8%

uniQure N.V. (NASDAQ:QURE) saw a large growth in short interest in the month of December. As of December 31st, there was short interest totaling 11,996,689 shares, a growth of 33.8% from the December 15th total of 8,966,485 shares. Based on an average daily volume of 2,755,072 shares, the short-interest ratio is currently 4.4 days. Approximately 20.2% of the shares of the company are sold short. Approximately 20.2% of the shares of the company are sold short. Based on an average daily volume of 2,755,072 shares, the short-interest ratio is currently 4.4 days.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of uniQure in a report on Wednesday, October 8th. Mizuho lowered their price objective on uniQure from $60.00 to $33.00 and set an “outperform” rating for the company in a research report on Monday, December 8th. HC Wainwright reduced their target price on uniQure from $110.00 to $70.00 and set a “buy” rating on the stock in a research report on Tuesday, November 4th. Wall Street Zen downgraded shares of uniQure from a “hold” rating to a “sell” rating in a research note on Sunday, January 11th. Finally, Benchmark reaffirmed a “buy” rating on shares of uniQure in a research note on Tuesday, November 4th. Ten investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $60.82.

uniQure Price Performance

QURE stock opened at $22.84 on Friday. The firm has a market cap of $1.42 billion, a P/E ratio of -5.20 and a beta of 0.68. The company has a debt-to-equity ratio of 0.23, a quick ratio of 7.12 and a current ratio of 7.12. uniQure has a 1 year low of $7.76 and a 1 year high of $71.50. The stock has a 50-day simple moving average of $24.77 and a 200-day simple moving average of $27.72.

uniQure (NASDAQ:QURE) last announced its earnings results on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.53). The business had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $4.46 million. uniQure had a negative return on equity of 373.73% and a negative net margin of 1,492.90%. On average, equities analysts predict that uniQure will post -3.75 earnings per share for the current fiscal year.

Insider Activity at uniQure

In other uniQure news, Director Jack Kaye sold 38,810 shares of the business’s stock in a transaction on Tuesday, November 4th. The shares were sold at an average price of $30.34, for a total transaction of $1,177,495.40. Following the sale, the director directly owned 20,439 shares in the company, valued at approximately $620,119.26. The trade was a 65.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Robert Gut sold 31,434 shares of the business’s stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $27.26, for a total transaction of $856,890.84. Following the sale, the director directly owned 40,145 shares in the company, valued at approximately $1,094,352.70. This represents a 43.92% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 102,247 shares of company stock worth $2,839,298 in the last quarter. 4.79% of the stock is currently owned by insiders.

Institutional Trading of uniQure

Several institutional investors have recently added to or reduced their stakes in QURE. Woodline Partners LP grew its stake in uniQure by 25.0% in the first quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock worth $1,864,000 after purchasing an additional 35,175 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of uniQure during the 2nd quarter valued at approximately $117,000. Aberdeen Group plc boosted its holdings in uniQure by 24.2% in the second quarter. Aberdeen Group plc now owns 2,750,714 shares of the biotechnology company’s stock worth $38,345,000 after purchasing an additional 535,163 shares during the period. Y Intercept Hong Kong Ltd bought a new stake in uniQure during the second quarter valued at $872,000. Finally, Teacher Retirement System of Texas bought a new position in shares of uniQure in the 2nd quarter worth about $151,000. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.